2021

1. The cost-effectiveness of isavuconazole compared to voriconazole, the standard of care in the treatment of patients with invasive mould diseases, prior to differential pathogen diagnosis in Spain

   Mycoses, Vol. 64, Núm. 1, pp. 66-77